Hinge Health Inc. (HNGE) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, HNGE scores 68 out of 100 with a letter grade of C+, labeled "Roarable Hold — Upper Neutral / Watch for Breakout." The five pillars are: Fundamental Cash Engine at 13/20 (ROIC of -35% and FCF yield of 1.81%), Whale 13F Flow at 19/20 (institutional accumulation and options positioning), Insider Conviction at 10/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 10/20 (beta of 1.24 and sector sensitivity), and Forensic Balance Sheet at 16/20 (Altman Z of 12.12, Piotroski F of 7/9, Debt/Equity of 0.86).

For a prospective investor, the profile is split. The strongest pillar is institutional flow, which is the main upside driver in this rating. The weakest pillars are operating cash generation and insider conviction, which means the fundamental engine and insider signals do not currently support the same conviction as the positioning data. The forensic balance sheet is a relative strength, supported by the Altman Z and Piotroski readings. Macro fit is moderate: a beta of 1.24 implies above-market sensitivity to broad moves. The forward P/E of 29 is a valuation tradeoff that rests on future earnings expectations, which the source data does not establish. The rating's "watch for breakout" framing reflects that the outcome depends on whether flow and fundamentals converge, not on any single pillar.

Hinge Health Inc. is a NYSE-listed issuer classified in the Technology sector and the EDP Services industry, per the company profile. The source data does not describe its products, customers, or revenue model. Gross margin of 79.6% is reported in the market data section. Source data does not provide further detail on how the company makes money.

Per the SEC financials, revenue grew from $292.7M (FY 2023) to $587.9M (FY 2025), while operating and net losses widened to $-546.4M and $-528.3M in FY 2025. Reported operating margin is -60% and net margin is -60%, and ROIC is -35%. The Altman Z-Score is 12.12 and the Piotroski F-Score is 7/9, per the Roarable RQD rating. Debt/Equity is 0.86 per the same source. Reported debt fell from $1214.0M (FY 2023) to $164.8M (FY 2025), and cash was $208.0M at FY 2025.

Per the recent news and catalysts feed, five items are listed, all tied to HNGE. Two are flagged as catalysts (green) and three as market wire (yellow). The most recent item is a Yahoo Finance piece titled "Reasons to Hold Hinge Health Stock in Your Portfolio for Now." A Seeking Alpha piece is titled "Hinge Health: Great Business, Expensive Stock." An Investing.com item reports the stock "hits all-time high at 100.4 USD." A Yahoo Finance item reports a "Modest Fair Value Lift As Analysts Raise Targets." A TradingView item reports a 12-month price target raised to $113.38, which it says implies 3% upside.

Risk watch items from the headlines include the valuation characterization ("Expensive Stock") and the fact that the source's stated 52-week high of $117.55 is above the 100.4 all-time-high level cited in a separate headline, so the high reference points should be reconciled. The Butterfly Supply-Chain Graph lists supply chain as NONE, no butterfly links, and no proprietary signals.

Per the Butterfly Supply-Chain Graph, the supply chain is NONE, with no butterfly links and no proprietary signals. The source data therefore does not identify upstream suppliers, downstream customers, or sector correlations. Second-order ripples cannot be mapped from the provided data. A prospective investor should note that the absence of linkage data is itself a gap, not evidence of independence.

Analyst data is NONE, so no consensus rating is available. Holders data is NONE, so no SEC Form 4 insider, 13F institutional, or Congressional trades are available from the source. The only price-target reference comes from a TradingView headline citing a raised 12-month target of $113.38. The Roarable RQD rating's whale flow pillar (19/20) reflects institutional accumulation and options positioning, but the underlying holder-level data is not provided.

• What is the trailing P/E and EV/EBITDA, which are both marked not available in the source data?
• What drives the gap between the reported FY 2025 net loss of $-528.3M and the positive FCF of $170.7M?
• What is the company's product, customer, and revenue mix behind the 79.6% gross margin?
• Who are the institutional and insider holders underlying the whale flow and insider conviction pillar scores?
• Why is the EPS for each reported fiscal year listed as N/A in the SEC financials?